Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis
Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis
April 24, 2017 (Issue: 1519)
The FDA has approved dupilumab (Dupixent – Sanofi/Regeneron), a subcutaneously-injected fully human
monoclonal antibody, for treatment of adults with
moderate to severe atopic dermatitis (eczema) that
has not responded to topical therapies. It...more
- M Kraft and M Worm. Dupilumab in the treatment of moderate-to-severe atopic dermatitis. Expert Rev Clin Immunol 2017; 13:301.
- Crisaborole (Eucrisa) for atopic dermatitis. Med Lett Drugs Ther 2017; 59:34.
- Drugs for allergic disorders. Med Lett Drugs Ther 2017; 59 (in press).
- LA Beck et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371:130.
- EL Simpson et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375:2335.
- A Blauvelt et al. Long-term management of moderate-to-severe atopic dermatitis (AD) with dupilumab and concomitant topical corticosteroids (TCS): a 1-year, randomized, placebo-controlled phase 3 trial (CHRONOS). Presented at the 75th American Academy of Dermatology (AAD) Annual Meeting, Orlando, FL, March 3-7, 2017. Abstract 5267.
- MJ Cork et al. Pharmacokinetics, safety and efficacy of dupilumab in a pediatric population with moderate-to-severe atopic dermatitis: results from an open-label phase 2a trial. Presented at the 75th American Academy of Dermatology (AAD) Annual Meeting, Orlando, FL, March 3-7, 2017. Abstract 5279.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. April 5, 2017. Reprinted with permission by First Databank, Inc. All rights reserved. ©2017. www.fdbhealth.com/policies/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis
Article code: 1519b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
